NEW YORK, Nov. 9, 2016 /PRNewswire/ -- The global PEGylated proteins market is expected to USD 1,137.8 million by 2021 from USD 690.6 million in 2016, at a CAGR of 10.5% between 2016 and 2021. The growth of this market is mainly driven by increase in R&D spending of pharmaceutical & biotechnology companies, growth in biologics sector, high prevalence of lifestyle disease, and increase in adoption of protein based drugs over non-protein based drugs. In addition, rising opportunities in emerging markets, and top-selling biologics drugs going off-patent in the near future provides a growing opportunity to this market.
This report segments the global PEGylated proteins market by product, protein type, application and end-user. By product, the market includes consumables and services. Based on protein type, the market is segmented into colony stimulating factors, interferons, erythropoietin, mAbs, and recombinant factor VIII. The colony stimulating factors segment will hold the largest share of the PEGylated proteins type market in 2016.
The geographic segments included in this report are North America, Europe, Asia, and Rest of the World (RoW). North America is expected to account for the largest share in the global the PEGylated proteins market in 2016. Asia is expected to register the fastest growth in the forecast period.